Colistin nephrotoxicity increases with age

Scandinavian Journal of Infectious Diseases

Volumn 46, Issue 10, 2014, Pages 678-685

  Balkan, Ilker Inanc ^a   Dogan, Mustafa ^b   Durdu, Bulent ^c   Batirel, Ayse ^d   Hakyemez, Ismail N ^e   Cetin, Birsen ^f   Karabay, Oguz ^g   Gonen, Ibak ^h   Ozkan, Ahmet Selim ⁱ   Uzun, Sami ^j   Demirkol, Muhammed Emin ^a   Akbas, Sedat ^a,k   Kacmaz, Asiye Bahar ^a   Aras, Sukru ^l   Mert, Ali ^a,m   Tabak, Fehmi ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Namk Kemal University   (Turkey)

^c Bakirkoy Sadi Konuk Training and Research Hospital   (Turkey)

^d Kartal Lutfi Kirdar Training and Research Hospital   (Turkey)

^e BEZMIALEM VAKIF UNIVERSITY   (Turkey)

^f KOÇ UNIVERSITY   (Turkey)

^g SAKARYA UNIVERSITY   (Turkey)

^h SULEYMAN DEMIREL UNIVERSITY   (Turkey)

ⁱ INONU UNIVERSITY   (Turkey)

^j HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^k Kiziltepe State Hospital   (Turkey)

^l Biostatistics   (Turkey)

^m ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

more..

Author keywords

Age; Colistin; Nephrotoxicity

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOPERAZONE PLUS SULBACTAM; CEFTAZIDIME; COLISTIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; SULBACTAM; TIGECYCLINE; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; ACUTE KIDNEY FAILURE; ADULT; AGE DISTRIBUTION; ARTICLE; BACTEREMIA; BLOODSTREAM INFECTION; CATHETER INFECTION; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DRUG INDICATION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINITIS; MENINGITIS; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; NEPHROTOXICITY; NEUROTOXICITY; PARESTHESIA; PATIENT REFERRAL; PNEUMONIA; RECEIVER OPERATING CHARACTERISTIC; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; RISK FACTOR; SURGICAL INFECTION; TREATMENT OUTCOME; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA; AGE; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; COMORBIDITY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ACUTE KIDNEY INJURY; ADMINISTRATION, INTRAVENOUS; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; COLISTIN; COMORBIDITY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

EID: 84907147374     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2014.926021     Document Type: Article

References (32)

1. Ministry of Health of Turkey. National nosocomial surveillance network annual report. Ankara, Turkey; 2010. Available at:http://hastaneenfeksiyonlari.saglik.gov.tr/dosya/analiz-2010.pdf (accessed February 2014).
2. Yahav D, Farbman L, Leibovici L, Paul M. Colistin:new lessons on an old antibiotic. Clin Microbiol Infect 2012; 18:18-29.
3. Falagas ME, Kasiakou SK. Colistin:the revival of polymyx-ins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333-41.
4. Falagas ME, Rafailidis PI. Nephrotoxicity of colistin:new insight into an old antibiotic. Clin Infect Dis 2009; 48:1729-31.
5. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure-defi nition, outcome measures, animal models, fl uid therapy and information technology needs:the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-12.
6. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-12.
7. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies:development and validation. J Chronic Dis 1987; 40:373-83.
8. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II:a severity of disease classifi cation system. Crit Care Med 1985; 13:818-29.
9. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria:an international expert proposal for interim standard defi nitions for acquired resistance. Clin Microbiol Infect 2012; 18:268-81.
10. Daikos GL, Skiada A, Pavleas J, Vafiadi C, Salatas K, Tofas P, et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J Chemother 2010; 22:175-8.
11. Lim LM, Ly N, Anderson D, Yang JC, Macander L, Jarkowski A, et al. Resurgence of colistin:a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmaco-therapy 2010; 30:1279-91.
12. Falagas ME, Rizos M, Bliziotis IA, Rellos K, Kasiakou SK, Michalopoulos A. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005; 5:1.
13. Pintado V, San Miguel LG, Grill F, Mej í a B, Cobo J, Fortún J, et al. Intravenous colistin sulphomethate sodium for therapy of infections due to multidrug-resistant Gram-negative bacteria. J Infect 2008; 56:185-90.
14. Cheng CY, Sheng WH, Wang JT, Chen YC, Chang SC. Safety and effi cacy of intravenous colistin (colistin meth-anesulphonate) for severe multidrug-resistant Gram-negative bacterial infections. Int J Antimicrob Agents 2010; 35:297-300.
15. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) Gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006; 25:596-9.
16. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis 2009; 48:1724-8.
17. Deryke CA, Crawford AJ, Uddin N, Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010; 54:4503-5.
18. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimi-crob Agents 2009; 34:434-8.
19. Ko HJ, Jeon MH, Choo EJ, Lee EJ, Kim TH, Jun JB, et al. Early acute kidney injury is a risk factor that predicts mortality in patients treated with colistin. Nephron Clin Pract 2011; 117:284-8.
20. Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect 2011; 62:187-90.
21. Kwon JA, Lee JE, Huh W, Peck KR, Kim YG, Kim DJ, Oh HY. Predictors of acute kidney injury associated with intravenous colistin treatment. Int J Antimicrob Agents 2010; 35:473-7.
22. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin:a prospective evaluation. Int J Antimicrob Agents 2005; 26:504-7.
23. Sorlí L, Luque S, Grau S, Berenguer N, Segura C, Montero MM, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity:a prospective observational cohort study. BMC Infect Dis 2013; 13:380.
24. Pogue JM, Lee J, Marchaim D, Yee V, Zhao JJ, Chopra T. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53:879-84.
25. Doshi NM, Mount KL, Murphy CV. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 2011; 31:1257-64.
26. Collins JM, Haynes K, Gallagher JC. Emergent renal dysfunction with colistin pharmacotherapy. Pharmacotherapy 2013; 33:812-6.
27. Rocco M, Montini L, Alessandri E, Venditti M, Laderchi A, De Pascale G, et al. Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistinmethanesulfonate and/or other nephrotoxic antibiotics:a retrospective cohort study. Crit Care 2013; 17:R174.
28. Reina R, Estenssoro E, Sáenz G, Canales HS, Gonzalvo R, Vidal G, et al. Safety and effi cacy of colistin in Acinetobacter and Pseudomonas infections:a prospective cohort study. Intensive Care Med 2005; 31:1058-65.
29. Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician 2008; 78:743-50.
30. Levin AS, Barone AA, Penço J, Santos MV, Marinho IS, Arruda EA, et al. Intravenous colistin as therapy for nosoco-mial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999; 28:1008-11.
31. Falagas ME, Kasiakou SK. Toxicity of polymyxins:a systematic review of the evidence from old and recent studies. Crit Care 2006; 10:R27.
32. Gauthier TP, Wolowich WR, Reddy A, Cano E, Abbo L, Smith LB. Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patients. Antimicrob Agents Chemother 2012; 56:2392-6.